NewsRoom Articles - Page 6 of 202

TuesdayMar 11, 2025 10:00 am

Study Finds Experimental Drug Prolongs the Survival of Glioblastoma Patients

A recent study whose findings appeared in the Nature Communications journal has shown that a new experimental drug can increase the survival time of patients who have been diagnosed with glioblastoma. This brain cancer is the most prevalent brain cancer in adults. The experimental drug, dubbed 186RNL (Rhenium Obisbemeda), was developed at UT Health San Diego. The trial established that this drug candidate, at the very least, doubled the progression-free and survival duration of study participants in comparison to the known progression-free or survival rates of patients afflicted by this brain tumor. It also didn’t have any side effects that…

FridayMar 07, 2025 10:00 am

Bacterial Imbalances Have a Link to Multiple Sclerosis, Study Finds

Approximately a million Americans suffer from multiple sclerosis (MS), and globally, more than 2.8 million individuals have this condition. Several factors are thought to play a role in the development of this autoimmune condition, such as genetics, environmental factors, infectious disease, diet, and gut health. A new study has shown that imbalances in certain types of gut bacteria not only strongly indicate the likelihood of this illness developing but could also be a pointer to the severity of the disease in affected individuals. The researchers discovered that the ratio of two specific bacteria in the gut was a strong predictor…

FridayMar 07, 2025 10:00 am

Adageis Secures $2M Seed Funding to Expand AI-Driven Healthcare Solutions

Adageis closed a $2 million seed round at the end of Q4 2024 to support operational expansion, with the funding to enhance backend operations for next-generation software upgrades. Upgraded Electronic Health Record EHR”) connectivity will facilitate integration with over 90 EHR systems, while increased sales force investment will help accelerate growth and market adoption. Adageis’ AI-powered platform is designed to streamline healthcare operations, optimize provider revenue, and improve patient care outcomes. Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, has secured $2 million in seed financing to enhance its operations and…

ThursdayMar 06, 2025 10:00 am

Why it is Important to Ensure the Stability of Medicare Advantage

About 34 million Americans are enrolled in Medicare Advantage plans and these older people as well as people with disabilities depend on these plans to get access to quality healthcare at an affordable cost. MA plans offer additional coverage, such as dental care, preventive screenings, transportation assistance and other such care that is critical for maintaining the health of these seniors. Recently, the CMS approved a 4.33 percent increase in the payment for MA plans with effect from 2026. This increase means approximately $21 billion will be added to the funds available to support MA plans, something that will go…

WednesdayMar 05, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform

Calidi’s RTNova platform leverages engineered enveloped vaccinia viruses designed for systemic delivery. Calidi’s groundbreaking virotherapy holds “immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors,” says CEO. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies for cancer treatment. Most recently, the company has captured the spotlight for the development of its proprietary systemic platform, RTNova (https://ibn.fm/Z4pM3). The platform represents a significant advancement in systemic virotherapy, particularly in the utilization of enveloped virotherapies to target metastatic tumors across the body. Antitumor virotherapy employs viruses that selectively infect and…

WednesdayMar 05, 2025 10:45 am

Clene Inc. (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit on March 11

The Q1 Virtual Investor Summit will focus on microcap companies that are undervalued, and aim to create connections between leading investors and microcap companies Clene’s presentation will be given by CEO Rob Etherington and CFO Morgan Brown Clene’s participation in the event comes as the company is moving closer to submitting a New Drug Application to the FDA to secure potential accelerated approval for CNM-Au8® for ALS The company recently partnered with German-based APST Research GmbH to analyze neurofilament light chain (“NfL”) data for evaluating CNM-Au8 efficacy in ALS patients. Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene…

TuesdayMar 04, 2025 10:00 am

Scientists Say Brain Stimulations Hold Potential in Treating Anxiety in Parkinson’s Sufferers

Researchers studying brain waves have suggested that a new discovery they have made could hold the key to treating anxiety in people diagnosed with Parkinson’s disease. For a long time, DBS (deep brain stimulation) has been leveraged in the management of the physical symptoms linked to Parkinson’s, such as tremor, slowness and body stiffness. This new research suggests that DBS can take advantage of a specific brain wave and help treat anxiety in those with Parkinson’s disease. Doctor Lucia Ricciardi, who co-led the study and works at University of London, explained that anxiety is a serious unmet medical need among…

FridayFeb 28, 2025 11:00 am

Clene Inc. (NASDAQ: CLNN) Leverages APST’s NfL Database to Support FDA-Recommended Analyses for ALS Drug

Clene is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data for evaluating CNM-Au8® in ALS patients. APST maintains one of the largest ALS biomarker databases, with data from over 4,300 ALS patients, including clinical outcomes and biomarker tracking. The analysis will compare NfL changes in the NIH-sponsored Expanded Access Program (“EAP”) participants with historical ALS patient data to assess CNM-Au8’s potential efficacy. Clene plans to submit its statistical analysis plan to the FDA, aiming for filing of an NDA for potential accelerated approval in the second half of 2025. No significant safety concerns have been reported…

FridayFeb 28, 2025 10:00 am

Layoffs, Upheaval at CDC Trigger Fears on Handling Disease Outbreaks

America is facing threats of infectious diseases on multiple fronts; cases of measles are escalating in Texas and the surrounding states, bird flu is spreading across the country, and cases of polio and Ebola abroad pose an added risk to Americans due to international travel. Amid all these threats of infectious diseases, the U.S. CDC is experiencing mass layoffs and a great deal of uncertainty triggered by Trump’s efforts to downsize federal health agencies and reduce government spending. The firings have put a strain on personnel numbers within the CDC and it is getting harder to respond appropriately to any…

ThursdayFeb 27, 2025 10:45 am

Adageis Drives Value-Based Care Transition as Healthcare Switches from Artificial General Intelligence to Specific Use Cases

Healthcare providers are increasingly prioritizing specific, high-impact AI applications that enhance patient care and financial performance. Adageis' ProActive Care Platform leverages AI to enhance risk assessment, workflow optimization, and revenue tracking for providers. AI-driven patient monitoring and early intervention reduce hospital readmissions and improve care quality. Adageis’ Patented Risk Engine helps healthcare providers proactively address high-risk patients, improving outcomes while increasing reimbursements. Seamless integration with multiple EHR systems ensures easy adoption without disrupting provider workflows. As in other areas, artificial intelligence is making a measurable impact on healthcare, but the focus is shifting. While artificial general intelligence (“AGI”) once dominated…